Notice names this product. Par Health USA’s Buprenorphine Hydrochloride is named in FDA Class II recall D-0876-2026. Your particular item is not yet verified. Compare the identifiers and exclusions in the notice before deciding whether it applies. Agency-reported hazard: Crystallization Identifying details: Lot#:83912, Exp Date 10/2026 Lot#:84234, Exp Date 11/2026 Lot#:84990, Exp Date 11/2026 Lot#:85003, Exp Date 12/2026 Lot#:86443, Exp Date 01/2027 Lot#:89909, Exp Date 05/2027. Units affected: 154210 bottles. Status: Ongoing.
This notice names a product; your particular item is not yet verified. Compare every applicable model, serial, lot, production-date or model-year boundary below.
Buprenorphine Hydrochloride, Injection 0.3 mg/mL, Rx Only, 5 x 1 mL Single Dose Vials, Manufactured for: Endo USA, Malvern, PA, NDC 42023-179-05
Still to verify: match the label on your item with the full official notice, including any exclusions, tables and photos. Some identifiers appear only on the agency website and are absent from this data feed. A missing field does not mean all versions are affected.
If your lot or date falls outside a stated range, this notice has not established that your item is affected. This is not a finding about other recalls or product safety.
Crystallization
Company / brand: Par Health USA recalls
Affected product: Buprenorphine Hydrochloride recall status
Official ID D-0876-2026 · Official record ↗
See all Par Health USA recalls →
Found something wrong or missing? Report a data error.
Compiled from connected official public-domain government data. Sources last checked October 22, 2026 at 12:00 PM UTC.